13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001618205
Total reported value
$213.8M
$213.8M
68 檔
28.7%
The Q1 2025 SEC filing reveals that Birchview Capital, LP held a total portfolio value of $213.8M, covering 68 public equity positions.
In Q1 2025, Birchview Capital, LP displayed an active expansion posture, initiating 68 new positions and adding to 0 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including BMY, CORT, ACAD) accounted for 28.7% of total reported equity market value during Q1 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 36.29% | -2.56% | +0.00% | |
| 2 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 6.55% | +1.25% | -10.81% | |
| 3 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 3.80% | -0.15% | -22.16% | |
| 4 | PRTA | Prothena Corporation plc | Stock-Other | 3.58% | -0.42% | +9.32% | |
| 5 | ✓ | Biodesix Inc | Stock-Other | 3.11% | +0.65% | — | |
| 6 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 2.90% | +0.10% | — | |
| 7 | ELUT | Elutia Inc | Stock-Other | 2.61% | -0.02% | -3.08% | |
| 8 | AXGN | Axogen Inc | Stock-Other | 2.59% | — | -18.27% | |
| 9 | PHR | Phreesia Inc | Stock-Other | 2.55% | -0.07% | EXIT | |
| 10 | TVTX | Travere Therapeutics Inc | Stock-Other | 2.15% | +0.28% | -6.76% | |
| 11 | QDELUSD | Quidelortho CORP | Stock-Other | 2.05% | -0.04% | — | |
| 12 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 2.02% | -0.09% | +0.00% | |
| 13 | UTHR | United Therapeutics CORP | Stock-Healthcare | 2.01% | -0.38% | -25.00% | |
| 14 | DCGO | Docgo Inc | Stock-Other | 1.98% | — | +13.09% | |
| 15 | OVV | Ovintiv Inc | Stock-Energy | 1.94% | -0.98% | — | |
| 16 | HROW | Harrow Inc | Stock-Other | 1.68% | — | — | |
| 17 | MASI* | Masimo CORP | Stock-Other | 1.63% | — | -26.18% | |
| 18 | EQT | Eqt CORP | Stock-Energy | 1.61% | -0.39% | — | |
| 19 | CSTL | Castle Biosciences Inc | Stock-Other | 1.54% | -0.04% | +13.34% | |
| 20 | ALKS | Alkermes plc | Stock-Healthcare | 1.43% | +0.22% | — | |
| 21 | STOK | Stoke Therapeutics Inc | Stock-Other | 1.21% | -1.16% | +0.00% | |
| 22 | TMCI | Treace Medical Concepts Inc | Stock-Other | 1.20% | — | +2.23% | |
| 23 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 0.99% | -0.13% | — | |
| 24 | QURE | uniQure N.V. | Stock-Other | 0.82% | +0.15% | +343.49% | |
| 25 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.67% | -0.65% | EXIT | |
| 26 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.61% | -0.11% | +110.00% | |
| 27 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.61% | +0.11% | +50.00% | |
| 28 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.58% | — | +0.02% | |
| 29 | HALO | Halozyme Therapeutics Inc | Stock-Healthcare | 0.55% | +0.85% | — | |
| 30 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.50% | -0.74% | EXIT | |
| 31 | NVCR | NovoCure Limited | Stock-Healthcare | 0.48% | -1.26% | EXIT | |
| 32 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.45% | — | +100.00% | |
| 33 | KIDS | Orthopediatrics CORP | Stock-Other | 0.43% | — | — | |
| 34 | SLDB | Solid Biosciences Inc | Stock-Other | 0.41% | +0.54% | — | |
| 35 | INBX | Inhibrx Biosciences Inc | Stock-Other | 0.39% | — | — | |
| 36 | TXG | 10x Genomics Inc-class A | Stock-Other | 0.38% | — | — | |
| 37 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.35% | +0.07% | — | |
| 38 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 0.32% | — | -17.20% | |
| 39 | LUNG | Pulmonx CORP | Stock-Other | 0.30% | -0.06% | — | |
| 40 | CADL | Candel Therapeutics Inc | Stock-Other | 0.29% | +0.06% | — | |
| 41 | ATEC | Alphatec Holdings Inc | Stock-Other | 0.29% | — | -43.10% | |
| 42 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.28% | — | +0.75% | |
| 43 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.27% | — | +100.00% | |
| 44 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 0.27% | -0.32% | EXIT | |
| 45 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 0.26% | — | — | |
| 46 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.26% | -0.43% | EXIT | |
| 47 | XNCR | Xencor Inc | Stock-Other | 0.24% | — | — | |
| 48 | OMGBP | Outset Medical Inc | Stock-Other | 0.24% | -0.22% | EXIT | |
| 49 | 2655787D | Blueprint Medicines CORP | Stock-Other | 0.21% | — | — | |
| 50 | AM6 | Amicus Therapeutics Inc | Stock-Other | 0.20% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | BMY | Bristol-myers Squibb Co | — | NEW | New buy |
| 2 | CORT | Corcept Therapeutics Inc | — | NEW | New buy |
| 3 | ACAD | Acadia Pharmaceuticals Inc | — | NEW | New buy |
| 4 | PRTA | Prothena Corporation plc | — | NEW | New buy |
| 5 | ✓ | Biodesix Inc | — | NEW | New buy |
| 6 | NBIX | Neurocrine Biosciences Inc | — | NEW | New buy |
| 7 | ELUT | Elutia Inc | — | NEW | New buy |
| 8 | AXGN | Axogen Inc | — | NEW | New buy |
| 9 | PHR | Phreesia Inc | — | NEW | New buy |
| 10 | TVTX | Travere Therapeutics Inc | — | NEW | New buy |
| 11 | QDELUSD | Quidelortho CORP | — | NEW | New buy |
| 12 | PTGX | Protagonist Therapeutics Inc | — | NEW | New buy |
| 13 | UTHR | United Therapeutics CORP | — | NEW | New buy |
| 14 | DCGO | Docgo Inc | — | NEW | New buy |
| 15 | OVV | Ovintiv Inc | — | NEW | New buy |
| 16 | HROW | Harrow Inc | — | NEW | New buy |
| 17 | MASI* | Masimo CORP | — | NEW | New buy |
| 18 | EQT | Eqt CORP | — | NEW | New buy |
| 19 | CSTL | Castle Biosciences Inc | — | NEW | New buy |
| 20 | ALKS | Alkermes plc | — | NEW | New buy |
| 21 | STOK | Stoke Therapeutics Inc | — | NEW | New buy |
| 22 | TMCI | Treace Medical Concepts Inc | — | NEW | New buy |
| 23 | FHTX | Foghorn Therapeutics Inc | — | NEW | New buy |
| 24 | QURE | uniQure N.V. | — | NEW | New buy |
| 25 | 4XC1 | Kalvista Pharmaceuticals Inc | — | NEW | New buy |
| 26 | XENE | Xenon Pharmaceuticals Inc | — | NEW | New buy |
| 27 | AXSM | Axsome Therapeutics Inc | — | NEW | New buy |
| 28 | KNSA | Kiniksa Pharmaceuticals International, plc | — | NEW | New buy |
| 29 | HALO | Halozyme Therapeutics Inc | — | NEW | New buy |
| 30 | RARE | Ultragenyx Pharmaceutical In | — | NEW | New buy |
| 31 | NVCR | NovoCure Limited | — | NEW | New buy |
| 32 | SRRK | Scholar Rock Holding CORP | — | NEW | New buy |
| 33 | KIDS | Orthopediatrics CORP | — | NEW | New buy |
| 34 | SLDB | Solid Biosciences Inc | — | NEW | New buy |
| 35 | INBX | Inhibrx Biosciences Inc | — | NEW | New buy |
| 36 | TXG | 10x Genomics Inc-class A | — | NEW | New buy |
| 37 | CYTK | Cytokinetics Inc | — | NEW | New buy |
| 38 | SWTXUSD | Springworks Therapeutics Inc | — | NEW | New buy |
| 39 | LUNG | Pulmonx CORP | — | NEW | New buy |
| 40 | CADL | Candel Therapeutics Inc | — | NEW | New buy |
| 41 | ATEC | Alphatec Holdings Inc | — | NEW | New buy |
| 42 | WVE | Wave Life Sciences Ltd. | — | NEW | New buy |
| 43 | MLTX | Moonlake Immunotherapeutics | — | NEW | New buy |
| 44 | APLSUSD | Apellis Pharmaceuticals Inc | — | NEW | New buy |
| 45 | BCRX | Biocryst Pharmaceuticals Inc | — | NEW | New buy |
| 46 | APGE | Apogee Therapeutics Inc | — | NEW | New buy |
| 47 | XNCR | Xencor Inc | — | NEW | New buy |
| 48 | OMGBP | Outset Medical Inc | — | NEW | New buy |
| 49 | 2655787D | Blueprint Medicines CORP | — | NEW | New buy |
| 50 | AM6 | Amicus Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Birchview Capital, LP reported a total U.S. public equity portfolio value of $213.8M across 68 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
BMY
市值: $41.8M
During Q1 2025, Birchview Capital, LP's top holdings by market value included BMY (36.3%)、CORT (6.5%)、ACAD (3.8%). The largest single position, BMY, represented 36.3% of total portfolio value.
In Q1 2025, Birchview Capital, LP made 68 total portfolio adjustments, initiating 68 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.